1Shigeto M,Katsura M,Matsuda M,et al. Nateglinide and mitiglinide,but not sulfonylureas, induce insulin secretion through a mechanism media ted by calcium release from endoplasmic reticulum. J Pharmacol Exp T her,2007,322:1-7.
2Reimann F, Proks P, Ashcroft FM. Effects of mitiglinide (S21403) on Kit6.2/SUR1, Kit6.2/SUR2 and Kit6. 2/SUR2B types of ATP-sensi tire potassium channel. Br J Pharmacol, 2001, 132 : 1542-1548.
3Ojirna K, Kiyono Y, Kojirna M. Pharmacological and clinical profile of mitiglinide calcium hydrate(Glufast), a new insulinotropic agent with rapid onset. Nippon Yakurigaku Zasshi, 2004,124 : 245-255.
4Moil Y, Ojima K, Fuujimori Y,et al. Effects of mitiglinide on glucoseinduced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats. Endocrine, 2006,29 : 309-315.
5Misawa K, Ichikawa K, Ojima K, et al. Effect of KAD-1229, a nonsulfonylurea hypo-glyeemic agent,on plasma glucose and insulin in streptozo tocin-induced diabetic dogs. Pharmacol,2001,62:65-72.
6Ichikawa K,Yamato T,Ojima K,et -al. Effect of KAD-1229,a novel hy poglycaemic agent,on plasma glucose levels after meal load in type 2 dia betic rats. Clin Exp Phramacol Physiol, 2002,29 : 423-427.
7LandgrafR Amidiabetic drug at every meal. Mraw Fortschr Med, 2000, 142: 29-30.
10Yoshihara T, Kumashiro N, Kanazawa Y, et al. Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus. Endocrin J, 2006,53 : 67-72.
2Pratley RE,Foley JE ,Dunning BE. Rapid actingin sulinotropic agents :restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharm Des, 2001 ; 7 (14) :1375-1397.
3Malaisse WJ, Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: The meglitinide family. Horm Metab Res, 1995,27:263-266.
4Yamato T, Ishikawa K, Ojima K, et al. Effects of KAD-1229 on postgrandial hyperglycemia after oral meal load in STZ-induced diabetic rats. Jpn J Pharmacol, 2001 - 85 (suppll) : AbstP-602.
5Misawa K, Ishikawa K, Oiima K, et al. Effects of KAD-1229,a nonsulfonylurea hypoglycemic agent,on plasma glucose and insulin in streptozotocin-induced diabetic dogs. Pharmacology.2001,62 (2) :65.
6Yamada N, Shigeta Y, Kaneko T,et al. Hypoglycemic effects and safety of a novel rapid-acting insulinotropic agent, KAD-1229, for NIDDM. Diabetes, 1996 ; 45 (Suppl 2) : Abst265.
7Ohnota H,Koizumi T,Tsutsumi N,et al. Novel rapld-and short-acting hypoglycemic agent, a calcium (2S)-2-benzyl-3- (cis-hexahydro-2-isoindolinylcarbonyl ) propionate (KAD-1229) that acts on the sulfonylurea receptor:Comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther, 1994,269 : 489 - 495.
8Ohnota H, Kitamura T, Kinukawa M, et al. A rapid-and short-acting hypoglycemic agent KAD-1229 improves post-prandial hypoglycernic agent KAD-1229 improves post-prandial hyperglycemia and diabetic complications in steptozotocln-induced non-insulin-dependent diabetes mellitus rats. JPN J Pharmacol, 1996,71:315-323.
9Ohnota H,Koizumi T,Tsutsumi N,et al.Novel rapid and short acting hypoglycemic agent,a calcium (2S) -2-benzyl-3-(cis-hexahydro-2-isoindoliny-lcarbonyl) Propionate (KAD-1229) that acts on the sulfonylurea receptor:Comparison of effects between KAD-1229 and gliclazide.J pharmacol Exp Ther,1994,269:489-495.
10Frank Reimann,Peter Proks and Frances M.Ashcroft Effects of mitiglinide(S 21403) on Kir6.2/SUR1,Kir6.2/SUR2 and Kir6.2/SUR2B types of ATP-sensitive potassium channel.Br J Pharmacol,2001,132:1542-1548.
6Satoru, Yamadal ,Mari Watanabe, Osamu Funae, et al. Effect of combination therapy of a rapid-acting insulin secretagogue (Glinide) with premixeA insulin in type 2 diabetes mellitus [ J]. 2007,46(23 ) : 1893-1897.
7Yasuhiro Sunaga, Tohru Gonoi, Tadao Shibasald, et al. The effects of mitiglinide ( KAD-1229 ), a new anti-diabetic drug, on ATP-sensitive K* channels and insulin secretion:comparison with the sulfonylureas and nateglinide[ J]. European Journal of Pharmacology,2001,431 ( 1 ) : 119-125.
8Makoto Shigeto, Masashi Katsura, Masafumi Matasude, et al. Nateglinide and mitiglinide,but not sulfonylureas,induce Insulin secretion through a mechanism mediated by calcium release from cndoplasmic reticulum[J]. The Journal of Pharmacology and Experimental Therapeutics,2007,322 ( 1 ) : 1-7.
9Assaloni R, Da Ros R, Quagliaro L, et al. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients[J]. Diabetologia, 2005,48 (9) : 1919-1924.
10Service FF, Molnar GD, Rosevear JW, et al. Mean amplitude of glycemic excursions, a measure of diabetic instability [ J ]. Diabetes, 19 ( 9 ) : 1893-1897.
